IGC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IGC Pharma Inc is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment range. The stock shows weak technical indicators, no significant positive catalysts, and poor financial performance. Additionally, there are no strong trading signals or recent news to support a buy decision.
The stock is showing bearish technical indicators. The MACD is negatively expanding below 0, the RSI is neutral at 37.379, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot support levels (Pivot: 0.275, S1: 0.255, S2: 0.244).
NULL. There are no recent news updates, no significant insider or hedge fund trading activity, and no congress trading data.
The net income remains negative at -1821000, and the EPS is stagnant at -0.
The broader market (S&P
also closed with a -1.79% change, reflecting a negative sentiment.
In 2026/Q2, revenue dropped significantly (-53.64% YoY) to 191,000. Net income improved slightly but remains negative (-1821000, up 6.06% YoY). EPS is unchanged at -0.02, and gross margin increased to 51.83 (up 7.84% YoY). Overall, the financials are weak and not supportive of a buy decision.
No analyst ratings or price target changes are available for this stock.
